The FDA's priority review status generally indicates a treatment's potential to provide significant improvements in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. This status could lead to a faster approval process for Tarlatamab, which would be beneficial for Amgen's stock in the short term as it may positively influence investor sentiment and the company's revenue prospects in the oncology segment.